Skip to main content
See who owns your news
Get Started
SubscribeLogin
Published • loading... • Updated

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

The proposed oral therapy could provide a non-invasive option for earlier-stage dry AMD, and prior studies involved about 2,100 people.

Summary by Joplin Globe
VAUGHAN, Ontario--(BUSINESS WIRE)--Oct 6, 2026-

3 Articles

Seeking AlphaSeeking Alpha
Lean Right

Bausch + Lomb makes progress on development of oral treatment for dry AMD (BLCO:NYSE)

Bausch + Lomb advances tonabersat (BL1243) for dry AMD after an FDA meeting, outlining its clinical development path and a 2027 trial start. Read more here.

·Ra'anana, Israel
Read Full Article
Joplin GlobeJoplin Globe
Reposted by
Financial PostFinancial Post
Center

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Oct 6, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources lean Right
67% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Joplin Globe broke the news on Tuesday, October 6, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

AMD icon

AMD

Vaughan icon

Vaughan

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal